person · Reporting owner

Reasons Bryan M.

Disclosed activity across 5 companies

Tapewire entity: 76959
SEC CIK: 0001553489

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aclaris Therapeutics, Inc.ACRS · Entity 5041	Director	June 01, 2024	June 04, 2024
Amneal Pharmaceuticals, Inc.AMRX · Entity 820	CFO	August 21, 2018	August 23, 2018
Keenova Therapeutics plcNONE · Entity 28960	EVP & CFO	July 31, 2025	August 04, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aclaris Therapeutics, Inc.

Report date June 01, 2024 · Filed June 04, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,732	Reported balance After 2024-06-01 transaction · row 1 1 source row Row 1 · 2024-06-01 · Exercise / conversion · Acquired 4,660 · Balance 28,732 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-06-01 · Exercise / conversion · Disposed 4,660 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vested on June 1, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The shares underlying these restricted stock units vested on June 1, 2024.

Amneal Pharmaceuticals, Inc.

Report date August 21, 2018 · Filed August 23, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	82,986	Reported balance After 2018-08-21 transaction · row 1 1 source row Row 1 · 2018-08-21 · Sale · Disposed 11,698 · Balance 82,986 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 to $23.78. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 to $23.78. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Keenova Therapeutics plc

Report date July 31, 2025 · Filed August 04, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	54,714	Reported balance After 2025-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-07-31 · Grant · Acquired 41,035 · Balance 54,714 F1: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. F2: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer.

F2: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Impax Laboratories, LLC

Report date May 04, 2018 · Filed May 08, 2018

Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-05-04 transaction · row 1 1 source row Row 1 · 2018-05-04 · Disposition to issuer · Disposed 53,423 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
Restricted Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-05-04 transaction · row 2 1 source row Row 2 · 2018-05-04 · Disposition to issuer · Disposed 20,566 · Balance 0 F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Amount represents net amount of shares exchanged after required tax withholding with respect to such vesting.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.35 · Expires 2027-03-02	Direct	Reported balance After 2018-05-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-05-04 · Disposition to issuer · Disposed 56,232 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.27 · Expires 2026-02-26	Direct	Reported balance After 2018-05-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-05-04 · Disposition to issuer · Disposed 63,095 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.70 · Expires 2025-02-26	Direct	Reported balance After 2018-05-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-05-04 · Disposition to issuer · Disposed 47,500 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.24 · Expires 2024-05-14	Direct	Reported balance After 2018-05-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-05-04 · Disposition to issuer · Disposed 55,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.99 · Expires 2023-05-15	Direct	Reported balance After 2018-05-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-05-04 · Disposition to issuer · Disposed 52,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").

F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Amount represents net amount of shares exchanged after required tax withholding with respect to such vesting.

F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.

Societal CDMO, Inc.

Report date April 08, 2024 · Filed April 08, 2024

Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2024-04-08 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-04-08 · Other · Disposed 217,429 · Balance 73,620 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 28, 2024, by and among the Issuer, CoreRx, Inc., a Florida corporation ("Parent") and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of April 8, 2024 (the "Effective Time") with the Issuer surviving the merger. At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $1.10 per Share in cash (the "Offer Amount"), subject to any applicable withholding taxes and without interest. Row 2 · 2024-04-08 · Disposition to issuer · Disposed 73,620 · Balance 0 F2: Represents restricted stock units granted under an Issuer equity plan ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU. Pursuant to the terms of the Merger Agreement, each outstanding RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each RSU then outstanding was cancelled and converted into a cash payment equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Offer Amount, without interest and subject to any withholding of taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80	Direct	Reported balance After 2024-04-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-04-08 · Disposition to issuer · Disposed 118,182 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74	Direct	Reported balance After 2024-04-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-04-08 · Disposition to issuer · Disposed 27,229 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 28, 2024, by and among the Issuer, CoreRx, Inc., a Florida corporation ("Parent") and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of April 8, 2024 (the "Effective Time") with the Issuer surviving the merger. At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $1.10 per Share in cash (the "Offer Amount"), subject to any applicable withholding taxes and without interest.

F2: Represents restricted stock units granted under an Issuer equity plan ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU. Pursuant to the terms of the Merger Agreement, each outstanding RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each RSU then outstanding was cancelled and converted into a cash payment equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Offer Amount, without interest and subject to any withholding of taxes.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 31, 2025 Filed Aug 4, 2025 20:47 UTC	Keenova Therapeutics plc NONE · Entity 28960	GrantRestricted Stock Units · Derivative	41,035	$0.00	$0.00	Disclosure SEC source: 0001104659-25-073784 · tm2522414-19_4seq1.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,714 Underlying: Ordinary Shares · 41,035 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. F2 · derivative.exercise_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026. F2 · derivative.expiration_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026. Read SEC document
January 01, 2025 Filed Jan 2, 2025 17:01 UTC	Keenova Therapeutics plc NONE · Entity 28960	Exercise / conversionRestricted Stock Units · Derivative	6,838	$0.00	$0.00	Disclosure SEC source: 0001104659-25-000368 · tm2432211-10_4seq1.xml · derivative · entry 3 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,679 Underlying: Ordinary Shares · 6,838 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. F3 · derivative.exercise_date: On February 2, 2024, the reporting person was granted 20,517 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. F3 · derivative.expiration_date: On February 2, 2024, the reporting person was granted 20,517 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Read SEC document
January 01, 2025 Filed Jan 2, 2025 17:01 UTC	Keenova Therapeutics plc NONE · Entity 28960	Tax withholdingOrdinary Shares	1,724	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-000368 · tm2432211-10_4seq1.xml · nonDerivative · entry 2 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,114 F2 · price: The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the issuer's ordinary shares are not listed or quoted on a recognized trading market. Read SEC document
January 01, 2025 Filed Jan 2, 2025 17:01 UTC	Keenova Therapeutics plc NONE · Entity 28960	Exercise / conversionOrdinary Shares	6,838	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-000368 · tm2432211-10_4seq1.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. Read SEC document
June 01, 2024 Filed Jun 4, 2024 16:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015369 · form4-06042024_040618.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 1, 2024. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 1, 2024. Read SEC document
June 01, 2024 Filed Jun 4, 2024 16:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,660	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-015369 · form4-06042024_040618.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
April 08, 2024 Filed Apr 8, 2024 21:34 UTC	Societal CDMO, Inc. SCTL · Entity 92137	Disposition to issuerStock Option (Right to Buy) · Derivative	27,229	Not disclosed Strike: $0.74	Not disclosed	Disclosure SEC source: 0001104659-24-044896 · tm2411350-8_4seq1.xml · derivative · entry 4 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,229 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. Read SEC document
April 08, 2024 Filed Apr 8, 2024 21:34 UTC	Societal CDMO, Inc. SCTL · Entity 92137	Disposition to issuerStock Option (Right to Buy) · Derivative	118,182	Not disclosed Strike: $0.80	Not disclosed	Disclosure SEC source: 0001104659-24-044896 · tm2411350-8_4seq1.xml · derivative · entry 3 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,182 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. Read SEC document
April 08, 2024 Filed Apr 8, 2024 21:34 UTC	Societal CDMO, Inc. SCTL · Entity 92137	Disposition to issuerCommon Stock	73,620	$1.10	$80,982.00	Disclosure SEC source: 0001104659-24-044896 · tm2411350-8_4seq1.xml · nonDerivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units granted under an Issuer equity plan ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU. Pursuant to the terms of the Merger Agreement, each outstanding RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each RSU then outstanding was cancelled and converted into a cash payment equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Offer Amount, without interest and subject to any withholding of taxes. Read SEC document
April 08, 2024 Filed Apr 8, 2024 21:34 UTC	Societal CDMO, Inc. SCTL · Entity 92137	OtherCommon Stock	217,429	$1.10	$239,171.90	Disclosure SEC source: 0001104659-24-044896 · tm2411350-8_4seq1.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,620 F1 · shares: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 28, 2024, by and among the Issuer, CoreRx, Inc., a Florida corporation ("Parent") and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of April 8, 2024 (the "Effective Time") with the Issuer surviving the merger. At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $1.10 per Share in cash (the "Offer Amount"), subject to any applicable withholding taxes and without interest. Read SEC document
February 02, 2024 Filed Feb 6, 2024 16:31 UTC	Keenova Therapeutics plc NONE · Entity 28960	GrantRestricted Stock Units · Derivative	20,517	$0.00	$0.00	Disclosure SEC source: 0001104659-24-011128 · tm245307-13_4seq1.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,517 Underlying: Ordinary Shares · 20,517 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit (the "RSU") will be settled in ordinary shares of the issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. F2 · derivative.expiration_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. Read SEC document
November 14, 2023 Filed Nov 16, 2023 16:15 UTC	Keenova Therapeutics plc MNKTQ · Entity 28960	Disposition to issuerOrdinary Shares	96,660	$0.00	$0.00	Disclosure SEC source: 0001104659-23-119124 · tm2330745-13_4seq1.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland. F2 · kind: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy. F3 · kind: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014. Read SEC document
August 28, 2023 Filed Aug 28, 2023 16:32 UTC	Societal CDMO, Inc. SCTL · Entity 92137	PurchaseCommon Stock	62,500	$0.40	$25,000.00	Disclosure SEC source: 0001062993-23-017166 · form4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,049 F1 · kind: Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer. Read SEC document
August 17, 2023 Filed Aug 18, 2023 21:21 UTC	Keenova Therapeutics plc MNK · Entity 28960	Tax withholdingOrdinary Shares	15,976	$0.69	$11,071.37	Disclosure SEC source: 0001104659-23-093621 · tm2324159-4_4seq1.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,660 Read SEC document
June 30, 2023 Filed Jul 5, 2023 18:16 UTC	Keenova Therapeutics plc MNK · Entity 28960	Disposition to issuerRestricted Stock Units · Derivative	168,237	$0.00	$0.00	Disclosure SEC source: 0001104659-23-078291 · tm2320608-6_4seq1.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 168,237 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units (the "RSUs") granted on April 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors of Mallinckrodt's approval of a cash-based Key Employee Incentive Plan ("KEIP") that replaces the Company's existing 2023 short-term incentive and 2023 long-term incentive ("2023 LTI") programs for certain of its key officers, including the reporting person. Participation in the KEIP by the reporting person was subject to the cancelation of the reporting person's prior 2023 LTI program grants, including the reporting person's April 3, 2023 RSU grant. F1 · price: The restricted stock units (the "RSUs") granted on April 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors of Mallinckrodt's approval of a cash-based Key Employee Incentive Plan ("KEIP") that replaces the Company's existing 2023 short-term incentive and 2023 long-term incentive ("2023 LTI") programs for certain of its key officers, including the reporting person. Participation in the KEIP by the reporting person was subject to the cancelation of the reporting person's prior 2023 LTI program grants, including the reporting person's April 3, 2023 RSU grant. F1 · derivative.exercise_date: The restricted stock units (the "RSUs") granted on April 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors of Mallinckrodt's approval of a cash-based Key Employee Incentive Plan ("KEIP") that replaces the Company's existing 2023 short-term incentive and 2023 long-term incentive ("2023 LTI") programs for certain of its key officers, including the reporting person. Participation in the KEIP by the reporting person was subject to the cancelation of the reporting person's prior 2023 LTI program grants, including the reporting person's April 3, 2023 RSU grant. F1 · derivative.expiration_date: The restricted stock units (the "RSUs") granted on April 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors of Mallinckrodt's approval of a cash-based Key Employee Incentive Plan ("KEIP") that replaces the Company's existing 2023 short-term incentive and 2023 long-term incentive ("2023 LTI") programs for certain of its key officers, including the reporting person. Participation in the KEIP by the reporting person was subject to the cancelation of the reporting person's prior 2023 LTI program grants, including the reporting person's April 3, 2023 RSU grant. Read SEC document
June 02, 2023 Filed Jun 5, 2023 16:57 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034421 · doc4.xml · derivative · entry 4 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 2, 2023. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 2, 2023. Read SEC document
June 02, 2023 Filed Jun 5, 2023 16:57 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,507	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-034421 · doc4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 01, 2023 Filed Jun 5, 2023 16:57 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034421 · doc4.xml · derivative · entry 3 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 16:57 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $8.70	$0.00	Disclosure SEC source: 0001209191-23-034421 · doc4.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date. Read SEC document
May 17, 2023 Filed May 19, 2023 16:55 UTC	Societal CDMO, Inc. SCTL · Entity 92137	GrantStock Option (right to buy) · Derivative	27,229	$0.00 Strike: $0.74	$0.00	Disclosure SEC source: 0001062993-23-011843 · form4.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,229 Underlying: Common Stock · 27,229 shares Expires 2033-05-17 F2 · derivative.exercise_date: The stock option will vest in full on May 17, 2024, subject to continued service with the Company. Read SEC document
May 17, 2023 Filed May 19, 2023 16:55 UTC	Societal CDMO, Inc. SCTL · Entity 92137	GrantCommon Stock	73,620	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-011843 · form4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,549 F1 · price: These restricted stock units will vest in full on May 17, 2024, subject to continued service with the Company. Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
April 03, 2023 Filed Apr 5, 2023 19:06 UTC	Keenova Therapeutics plc MNK · Entity 28960	GrantRestricted Stock Units · Derivative	168,237	$0.00	$0.00	Disclosure SEC source: 0001104659-23-042299 · tm2311874-8_4seq1.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,237 Underlying: Ordinary Shares · 168,237 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit (the "RSU") may be settled in the discretion of the issuer in cash or ordinary shares of the issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest ratably on each of the first three anniversaries of the grant date. F2 · derivative.expiration_date: The RSUs will vest ratably on each of the first three anniversaries of the grant date. Read SEC document
December 14, 2022 Filed Dec 22, 2022 17:47 UTC	Keenova Therapeutics plc MNK · Entity 28960	GrantOrdinary Shares	112,636	$0.00	$0.00	Disclosure SEC source: 0001104659-22-129618 · tm2233304-3_4seq1.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,636 F1 · security: The reported ordinary shares represent restricted stock units, which will be settled in an equal number of MNK ordinary shares and will vest ratably on each of the first three anniversaries of August 17, 2022. Read SEC document
June 16, 2022 Filed Jun 21, 2022 18:23 UTC	Keenova Therapeutics plc MNKPF · Entity 28960	Disposition to issuerEmployee Share Options (Right to Buy) · Derivative	57,569	$0.00 Strike: $22.26	$0.00	Disclosure SEC source: 0000899243-22-023452 · doc4.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 57,569 shares Expires 2029-04-01 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document
June 16, 2022 Filed Jun 21, 2022 18:23 UTC	Keenova Therapeutics plc MNKPF · Entity 28960	Disposition to issuerOrdinary Shares	11,593	$0.00	$0.00	Disclosure SEC source: 0000899243-22-023452 · doc4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document
June 03, 2022 Filed Jun 6, 2022 17:33 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034606 · doc4.xml · derivative · entry 4 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 3, 2022. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 3, 2022. Read SEC document
June 03, 2022 Filed Jun 6, 2022 17:33 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	3,356	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-034606 · doc4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 02, 2022 Filed Jun 6, 2022 17:33 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034606 · doc4.xml · derivative · entry 3 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 Underlying: Common Stock · 4,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. Read SEC document
June 02, 2022 Filed Jun 6, 2022 17:33 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $14.48	$0.00	Disclosure SEC source: 0001209191-22-034606 · doc4.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2032-06-01 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. Read SEC document
May 18, 2022 Filed May 20, 2022 17:36 UTC	Societal CDMO, Inc. SCTL · Entity 92137	GrantStock Option (right to buy) · Derivative	118,182	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001062993-22-013172 · form4.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,182 Underlying: Common Stock · 118,182 shares Expires 2032-05-18 F2 · derivative.exercise_date: The stock option will vest in full on May 18, 2023, subject to continued service with the Company. Read SEC document
May 18, 2022 Filed May 20, 2022 17:36 UTC	Societal CDMO, Inc. SCTL · Entity 92137	GrantCommon Stock	87,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-22-013172 · form4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,929 F1 · price: These restricted stock units will vest in full on May 18, 2023, subject to continued service with the Company. Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:09 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038457 · doc4.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,356 Underlying: Common Stock · 3,356 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:09 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	12,250	$0.00 Strike: $21.90	$0.00	Disclosure SEC source: 0001209191-21-038457 · doc4.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2031-06-02 F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date. Read SEC document
April 20, 2021 Filed Apr 22, 2021 17:58 UTC	Societal CDMO, Inc. REPH · Entity 92137	GrantStock Option (right to buy) · Derivative	38,012	$0.00 Strike: $1.71	$0.00	Disclosure SEC source: 0001192482-21-000351 · edgar.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,012 Underlying: Common Stock · 38,012 shares Expires 2031-04-20 F2 · derivative.exercise_date: The stock option will vest on April 20, 2022. Read SEC document
April 20, 2021 Filed Apr 22, 2021 17:58 UTC	Societal CDMO, Inc. REPH · Entity 92137	GrantCommon Stock	26,923	$0.00	$0.00	Disclosure SEC source: 0001192482-21-000351 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,429 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on April 20, 2022. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document
April 20, 2021 Filed May 17, 2021 16:03 UTC Amendment	Societal CDMO, Inc. REPH · Entity 92137	GrantStock Option (right to buy) · Derivative	38,012	$0.00 Strike: $2.60	$0.00	Disclosure SEC source: 0001192482-21-000430 · edgar.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,012 Underlying: Common Stock · 38,012 shares Expires 2031-04-20 F1 · derivative.exercise_price: This amended Form 4 is being filed to correct a typographical error in the exercise price of the stock options acquired on April 20, 2021 as reported on the Form 4 filed on April 22, 2021. F2 · derivative.exercise_date: The stock option will vest on April 20, 2022. Read SEC document
December 03, 2020 Filed Dec 7, 2020 16:13 UTC	Keenova Therapeutics plc MNKKQ · Entity 28960	SaleOrdinary Shares	5,400	$0.17	$891.00	Disclosure SEC source: 0000950138-20-000521 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,593 Read SEC document
June 06, 2020 Filed Jun 8, 2020 17:46 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	7,333	$0.00	$0.00	Disclosure SEC source: 0001209191-20-035059 · doc4.xml · derivative · entry 3 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2020. F4 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2020. Read SEC document
June 06, 2020 Filed Jun 8, 2020 17:46 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	7,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-035059 · doc4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 04, 2020 Filed Jun 8, 2020 17:46 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantOption Grant (right to buy) · Derivative	16,500	$0.00 Strike: $1.41	$0.00	Disclosure SEC source: 0001209191-20-035059 · doc4.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-06-03 F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date. Read SEC document
May 07, 2020 Filed May 11, 2020 17:05 UTC	Societal CDMO, Inc. REPH · Entity 92137	GrantStock Option (right to buy) · Derivative	12,405	$0.00 Strike: $8.37	$0.00	Disclosure SEC source: 0001192482-20-000339 · edgar.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,405 Underlying: Common Stock · 12,405 shares Expires 2030-05-07 F2 · derivative.exercise_date: The stock option will vest on May 7, 2021. Read SEC document
May 07, 2020 Filed May 11, 2020 17:05 UTC	Societal CDMO, Inc. REPH · Entity 92137	GrantCommon Stock	8,363	$0.00	$0.00	Disclosure SEC source: 0001192482-20-000339 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,506 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on May 7, 2021. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document
April 01, 2020 Filed Apr 3, 2020 16:40 UTC	Keenova Therapeutics plc MNK · Entity 28960	Tax withholdingOrdinary Shares	986	$1.93	$1,902.98	Disclosure SEC source: 0000950138-20-000202 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,993 Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted stock units · Derivative	8,876	$0.00	$0.00	Disclosure SEC source: 0001209191-20-016088 · doc4.xml · derivative · entry 3 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted stock units · Derivative	8,876	$0.00	$0.00	Disclosure SEC source: 0001209191-20-016088 · doc4.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Underlying: Common Stock · 8,876 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	8,876	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-016088 · doc4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
December 05, 2019 Filed Dec 9, 2019 18:29 UTC	Societal CDMO, Inc. REPH · Entity 92137	GrantCommon Stock	9,156	$0.00	$0.00	Disclosure SEC source: 0001192482-19-000492 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,143 F1 · shares: These restricted stock units will vest in full on the earlier of (i) a change of control of Recro Pharma, Inc. (the "Company") (as defined in the Company's 2018 Amended and Restated Equity Incentive Plan) or (ii) December 5, 2020, subject to continued service with the Company. Read SEC document
June 07, 2019 Filed Jun 7, 2019 16:12 UTC	Keenova Therapeutics plc MNK · Entity 28960	PurchaseOrdinary Shares	5,400	$8.96	$48,383.46	Disclosure SEC source: 0000950138-19-000343 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,979 Read SEC document
June 06, 2019 Filed Jun 10, 2019 16:50 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	7,333	$0.00	$0.00	Disclosure SEC source: 0001209191-19-035830 · doc4.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,333 Underlying: Common Stock · 7,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. Read SEC document
May 09, 2019 Filed May 10, 2019 16:25 UTC	Societal CDMO, Inc. REPH · Entity 92137	GrantStock Option (right to buy) · Derivative	10,888	$0.00 Strike: $8.80	$0.00	Disclosure SEC source: 0001192482-19-000244 · edgar.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,888 Underlying: Common Stock · 10,888 shares Expires 2029-05-09 F2 · derivative.exercise_date: The stock option will vest on May 9, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.